(2S,3S,4S,5R,6S)-6-{4-[(2S,3R)-1-[4-fluoro(2H4)phenyl]-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl]phenoxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

• ChemBase编号: 168848
• 分子式: C30H29F2NO9
• 平均质量: 585.5493664
• 单一同位素质量: 585.18103795
• SMILES: c1cc(ccc1[C@H](CC[C@H]1C(=O)N([C@@H]1c1ccc(cc1)O[C@@H]1O[C@H]([C@@H](O)[C@H](O)[C@@H]1O)C(=O)O)c1ccc(cc1)F)O)F
• Canonical SMILES: OC(=O)[C@@H]1O[C@@H](Oc2ccc(cc2)[C@@H]2[C@@H](CC[C@@H](c3ccc(cc3)F)O)C(=O)N2c2ccc(cc2)F)[C@H]([C@H]([C@@H]1O)O)O
• InChI: InChI=1S/C30H29F2NO9/c31-17-5-1-15(2-6-17)22(34)14-13-21-23(33(28(21)38)19-9-7-18(32)8-10-19)16-3-11-20(12-4-16)41-30-26(37)24(35)25(36)27(42-30)29(39)40/h1-12,21-27,30,34-37H,13-14H2,(H,39,40)/t21-,22+,23-,24+,25+,26-,27+,30-/m1/s1
• InChIKey: UOFYCFMTERCNEW-ADEYADIWSA-N

名称和登记号

名称

• IUPAC标准名: (2S,3S,4S,5R,6S)-6-{4-[(2S,3R)-1-[4-fluoro(^2H₄)phenyl]-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl]phenoxy}-3,4,5-trihydroxyoxane-2-carboxylic acid
• IUPAC传统名: (2S,3S,4S,5R,6S)-6-{4-[(2S,3R)-1-[4-fluoro(^2H₄)phenyl]-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl]phenoxy}-3,4,5-trihydroxyoxane-2-carboxylic acid
• 别名: 4-[(2S,3R)-1-(4-Fluorophenyl-d4)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenyl β-D-Glucopyranosiduronic Acid; Ezetimibe-d4 Phenoxy Glucuronide; Sch 58235-d4 Glucuronide; Sch 60663-d4; Ezetimibe-d4 β-D-Glucuronide, >85%

登记号

• PubChem SID: 162262980
• PubChem CID: 49849666

理论计算性质

• Acid pKa: 3.2282856
• 质子受体: 9
• 质子供体: 5
• LogD (pH = 5.5): 0.36065388
• LogD (pH = 7.4): -0.82900447
• Log P: 2.6113343
• 摩尔折射率: 140.8735 cm^3
• 极化性: 55.29284 Å^3
• 极化表面积: 156.99 Å^2
• 可自由旋转的化学键: 9
• 里宾斯基五规则: false

分子性质

理化性质

• 溶解度: Methanol
• 外观: White Solid
• 熔点: 140-150°C

安全信息

• 保存条件: -20°C Freezer, Under Inert Atmosphere

详细说明

Toronto Research Chemicals - E975032

Phase-II labelled metabolite of Ezetimibe, an antihyperlipoproteinemic. A cholesterol absorption inhibitor.

参考文献

• van Heek, M., at al.: J. Pharmacol. Exp. Ther., 283, 157 (1997)
• van Heek, M., at al.: Brit. J. Pharmacol., 129, 1748 (2000)